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Background: Procalcitonin (PCT) is a polypeptide with several cationic aminoacids in its chemical structure and it is
a well known marker of sepsis. It is now emerging that PCT might exhibit some anti-inflammatory effects. The
present study, based on the evaluation of the in vitro interaction between PCT and bacterial lipopolisaccharide (LPS),
reports new data supporting the interesting and potentially useful anti-inflammatory activity of PCT.
Results: PCT significantly decreased (p< 0.05) the limulus amoebocyte lysate (LAL) assay reactivity of LPS from both
Salmonella typhimurium (rough chemotype) and Escherichia coli (smooth chemotype). Subsequently, the in vitro
effects of PCT on LPS-induced cytokine release were studied in human peripheral blood mononuclear cells (PBMC).
When LPS was pre-incubated for 30 minutes with different concentrations of PCT, the release of interleukin-10
(IL-10) and tumor necrosis factor alpha (TNFα) by PBMC decreased in a concentration-dependent manner after 24
hours for IL-10 and 4 hours for TNFα. The release of monocyte chemotactic protein-1 (MCP-1) exhibited a drastic
reduction at 4 hours for all the PCT concentrations assessed, whereas such decrease was concentration-dependent
after 24 hours.
Conclusions: This study provides the first evidence of the capability of PCT to directly neutralize bacterial LPS, thus
leading to a reduction of its major inflammatory mediators.Background
The procalcitonin (PCT), the precursor for the hormone
calcitonin (CT), is composed of 116-aminoacids and has
a molecular weight of 13 kDa. PCT was discovered by
Moya et al. in 1975, but its molecular structure was elu-
cidated nine years later [1,2]. The primary structure of
whole PCT includes some relevant polycationic motifs
(2–3 bibasic aminoacids within a sequence of four) [1].
In sepsis, the marked increase of PCT concentration in
serum has been reported [1,3].
The role of PCT as mediator of the sepsis cascade
received much less attention. A pro-inflammatory activ-
ity of PCT in the pathogenesis of sepsis has been sug-
gested based on immune-neutralization findings in two
animal species [3]. An anti-inflammatory effect of PCT* Correspondence: gm4106@gmail.com
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reproduction in any medium, provided the orighas been reported in very few studies [4-6], where the
scarcity of the models/outcomes used does not lead to
any firm conclusion. When human recombinant PCT
was added to endotoxin-stimulated human whole blood,
there was a marked decrease of the pro-inflammatory
cytokine TNFα [5]. Interestingly, a reduction in IL-1β by
administration of PCT was observed in the same animal
model, the septic hamster, used for the first experiment
of PCT immune-neutralization [6].
Lipopolysaccharide (LPS), the principal component of
the outer leaflet of the outer membrane of Gram-nega-
tive bacteria, is recognized as the most potent microbial
mediator implicated in the pathogenesis of sepsis seque-
lae and septic shock. Lipid A, the hydrophobic anchor of
LPS, produces most of the responses after its detection
by Toll-like receptor 4 (TLR-4).
Some LPS such as Salmonella typhimurium (S. typhi-
murium) LPS and Escherichia coli (E. coli) LPS, are well
known endotoxins of rough and smooth chemotype [7].Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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linked disaccharide of glucosamine, phosphorylated at
the 1 and 4′ positions and acylated at the 2, 3, 2′, and 3′
positions with R-3-hydroxymyristate [8].
Therapeutic strategies for the treatment of septic shock
in humans are currently focused on neutralization of the
LPS molecule and its many deleterious effects [9].
Our previous investigations [10,11] and studies from
other researchers [12], demonstrated that antimicrobial
peptides, as well as other biological effective molecules
sharing a polycationic structure [9], are able to neutralize
LPS. Since PCT also presents two/three relevant polyca-
tionic motifs, comparable to some of the physical-chem-
ical patterns of such antimicrobial peptides previously
studied, we investigated the in vitro interaction between
PCT and both rough and smooth chemotype LPS [7] by
limulus amoebocyte lysate (LAL) test. As PCT was able
to significantly decrease LAL assay reactivity in both
LPSs tested, the effects of PCT-pre-incubated LPS on the
release of cytokines in human peripheral blood mono-
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Figure 1 Neutralization by PCT of LPS from S. typhimurium and E. coli
reactivity was evaluated as O. D. (405 nm) by the chromogenic LAL test aft
with 0 pg/ml PCT (LPS 30 min), with 5000 pg/ml PCT (LPS + PCT 5000 30 m
means ± SEM of at least four experiments each carried out in duplicate. Sta
p< 0.05 was considered significant, whereas not significant (n.s.) difference
comparison with respective LPS type-stimulated PCT-untreated cells (LPS 30
horizontal line encompassing the two statistically compared bars.the mononuclear cell targeting chemokine (MCP-1), as
well as Th1, Th2 and Treg type cytokines were selected.Results
LPS-neutralizing activity of PCT
Following incubation of different concentrations of PCT
with LPS for 30 minutes, PCT at a concentration of
500 pg/ml, significantly decreased the LAL reactivity of
100 pg/ml of both the rough LPS chemotype (S. typhi-
murium LPS, p = 0.0010) and the smooth LPS chemo-
type (E. coli LPS, p = 0.0030) (Figure 1). Higher
(5000 pg/ml) (Figure 1) or lower (50 pg/ml) (data not
shown), concentrations of PCT did not produce any sig-
nificant change in LAL reactivity of the LPS assessed.PCT effects on LPS-induced cytokine release
After 4 and 24 hours incubation of human PBMC with
S. typhimurium LPS pre-incubated with PCT, the release
of TNFα, IL-10, IL-4 and MCP-1 was simultaneously
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er 30 minutes incubation of the above reported LPS concentration:
in), 500 pg/ml PCT (LPS + PCT 500 30 min). Results are presented as
tistical significance between groups was assessed by Student’s t test. A
was associated with a p≥ 0.05. Statistics were performed in























































Figure 2 In vitro effect of different concentrations of PCT on S. typhimurium LPS-induced release of TNFα in human PBMC evaluated by
cytokine biochip array. Human PBMC were cultured for 4 h (panel A), and 24 h (panel B) with the following mixtures which had been pre-
incubated at 37°C for 30 min : Sterile saline fluid (SF) plus 50 ng/ml PCT (SF + PCT 50); SF plus 500 ng/ml PCT (SF + PCT 500); SF plus 5000 ng/ml
PCT (SF + PCT 5000); LPS of S. typhimurium SL1102 (100 ng/ml) plus SF (LPS + SF); LPS (100 ng/ml) plus 50 ng/ml PCT (LPS + PCT 50); LPS (100 ng/
ml) plus 500 ng/ml PCT (LPS + PCT 500); LPS (100 ng/ml) plus 5000 ng/ml PCT (LPS + PCT 5000). Results are presented as means ± SEM of at least
four experiments each carried out in duplicate. Statistical significance between groups was assessed by Student’s t test. A p< 0.05 was considered
significant, whereas not significant (n.s.) difference was associated with a p ≥ 0.05. Statistics were performed in comparison with LPS-stimulated
PCT-untreated cells (LPS + SF), and the exact significance index is indicated on the top of the horizontal line encompassing the two statistically
compared bars.






























































Figure 3 In vitro effect of different concentrations of PCT on S. typhimurium LPS-induced release of MCP-1 evaluated by cytokine
biochip array. Human PBMC were cultured for 4 h (panel A), and 24 h (panel B) with the following mixtures which had been pre-incubated at
37°C for 30 min : Sterile saline fluid (SF) plus 50 ng/ml PCT (SF + PCT 50); SF plus 500 ng/ml PCT (SF + PCT 500); SF plus 5000 ng/ml PCT (SF + PCT
5000); LPS of S. typhimurium SL1102 (100 ng/ml) plus SF (LPS + SF); LPS (100 ng/ml) plus 50 ng/ml PCT (LPS + PCT 50); LPS (100 ng/ml) plus
500 ng/ml PCT (LPS + PCT 500); LPS (100 ng/ml) plus 5000 ng/ml PCT (LPS + PCT 5000). Results are presented as means ± SEM of at least four
experiments each carried out in duplicate. Statistical significance between groups was assessed by Student’s t test. A p< 0.05 was considered
significant, whereas not significant (n.s.) difference was associated with a p ≥ 0.05. Statistics were performed in comparison with LPS-stimulated
PCT-untreated cells (LPS + SF), and the exact significance index is indicated on the top of the horizontal line encompassing the two statistically
compared bars
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induced a substantial increase of all the cytokines evalu-
ated in human PBMC at both time points of 4 and 24
hours as expected.
When LPS was pre-incubated with PCT at different
concentrations, a decrease of the TNFα release was
observed for both time points, this reduction was con-
centration-dependent at 4 hours (Figure 2). The LPS-
induced release of TNFα after 4 hours of incubation was
significantly reduced by 500 ng/ml (p = 0.0453) and by
5000 ng/ml (p = 0.0168) of PCT in comparison to LPS
plus saline-treated PBMC.
Following 24 hours of incubation, TNFα release stimu-
lated by LPS was significantly diminished when PCT was
used at 50 (p = 0.0185), at 500 (p = 0.0240) and at
5000 ng/ml (p = 0.0253).
The levels of MCP-1 were drastically reduced after 4
hours for all the PCT concentrations (Figure 3A). More-
over after 24 hours, the MCP-1 release significantly
decreased following both 500 (p = 0.0397) and 5000 ng/
ml (p = 0.0116) of PCT (Figure 3B). In the same experi-






















Figure 4 In vitro effect of different concentrations of PCT on S. typhim
array. Human PBMC were cultured for 24 h with the following mixtures wh
plus 50 ng/ml PCT (SF + PCT 50); SF plus 500 ng/ml PCT (SF + PCT 500); SF
(100 ng/ml) plus SF (LPS + SF); LPS (100 ng/ml) plus 50 ng/ml PCT (LPS + PC
(100 ng/ml) plus 5000 ng/ml PCT (LPS + PCT 5000). Results are presented a
duplicate. Statistical significance between groups was assessed by Student’
in comparison with LPS-stimulated PCT-untreated cells (LPS + SF), and the e
encompassing the two statistically compared bars.showed a dose-dependent inhibition by PCT at 24 h that
was significant at a concentration of 50 (p = 0.0278), 500
(p = 0.0135) and 5000 ng/ml (p = 0.0205) of the polypep-
tide (Figure 4). After 4 hours, this cytokine exhibited
slower kinetic. Even though the release of IL-10 by PCT/
LPS-incubated PBMC was significantly (p< 0.05) lower
than in the supernatant of LPS alone-challenged PBMC,
the level of this cytokine was still quite low and perhaps
not biologically relevant (data not shown).
The release of IL-4 was not affected by PCT (data not
shown).
Direct assay (trypan blue test and acridine orange vital
staining) of cellular viability always indicated a percentage
of more than 95% viable cells in any experimental group,
even after 24 h of PBMC incubation, which would indicate
that the observed reduction in cytokine release may not be
due to cellular toxicity by PCT, LPS or both. Also cell
count was carried out at beginning and at the end of each
experiment and these values were not significantly differ-
ent. Therefore a decrease of cell number should be
excluded as a possible cause of reduced cytokine release,







urium LPS-induced release of IL-10 evaluated by cytokine biochip
ich had been pre-incubated at 37°C for 30 min: Sterile saline fluid (SF)
plus 5000 ng/ml PCT (SF + PCT 5000); LPS of S. typhimurium SL1102
T 50); LPS (100 ng/ml) plus 500 ng/ml PCT (LPS + PCT 500); LPS
s means ± SEM of at least four experiments each carried out in
t test. A p< 0.05 was considered significant. Statistics were performed
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The main and novel findings of the present study are the
PCT-induced decrease of bacterial LPS reactivity and the re-
duction of LPS- induced release of some cytokines/chemo-
kines by PCT in human PBMC. Previous studies from our
group [10,11] and from other investigators [12], demon-
strated that antimicrobial peptides (teicoplanin and magai-
nins) and other biological effective molecules presenting aFigure 5 Putative LPS binding sites on PCT molecule. Proposed LPS bin
(aminoacids 58–59 and aminoacids 93–95), ii) a cluster of hydrophobic resid
positively charged central residues with hydrophobic aminoacids in the pe
aminoacids in red and other aminoacids in orange. The LPS binding sites s
the proposed LPS binding sites, a deep rough LPS chemical structure is sho
translational processing products (N-ProCT, calcitonin and katacalcin) of pro
post-translational processing [1,3].polycationic structure, can neutralize both the LAL reactivity
and other effects of LPS including cytokine release [9,13].
An examination of the PCT primary structure reveals
that relevant polycationic motifs (sequence of at least 2–3
bibasic aminoacids within a sequence of four) are present
in the whole molecule. Therefore, the whole PCT mol-
ecule may account for binding and neutralizing the LPS as
well as inhibiting the LPS-stimulated mediators.ding sites include: i) 2–3 cationic aminoacids within a cluster of four
ues encompassed by basic aminoacids (82–92), iii) a group of
riphery (101–109). Hydrophobic aminoacids in blue, cationic
uggested by Japelj [14] and Bhattacharjya [15] are indicated. Close to
wed. Flat dashed lines indicate the limits of the three post-
calcitonin, while dashed forks encompass the peptides cleaved during
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evidence that neutralization of LPS follows interactions
between on one hand, positively charged and hydropho-
bic groups of the peptide and on the other hand, phos-
phates and hydrophobic acyl chains of the conserved
lipid A moiety. It has been demonstrated that in the
LPS-neutralizing peptide, the lipid A binding motif
includes a cluster of hydrophobic residues encompassed
by basic aminoacids [14].
More recently, other authors underlined the pivotal role
of a group of positively charged central residues with
hydrophobic aminoacids distributed in the periphery [15].
The whole PCT used in our study, exhibited a plausible
lipid A binding sequence between Pro82 and Pro91 [14].
Also a putative lipid A binding sequence can be found be-
tween Leu101 and Val109 [15] as illustrated in Figure 5.
It has also been reported that the need for structural
amphipathicity is probably not as an essential feature for
LPS binding/neutralization as is the proximity of certain
aminoacids (cationic and hydrophobic residues) within a
given sequence [16].
The effects of PCT on LPS reactivity in the LAL test
model suggest that PCT is equally active against both
rough and smooth chemotypes. The S. typhimurium
strain SL1102 exhibits a Re chemotype LPS (deep rough)
that has been previously reported as very toxic in an
in vivo experimental model [17]. The E. coli 0111:B4 has
a smooth chemotype endotoxin often used in studies
regarding LPS binding/neutralization [18]. Therefore
PCT targets the lipid A portion which is a common
structural feature of these LPSs.
Since the molecular weight of PCT is approximately
13,000 daltons and the molecular weight of deep rough
LPS is 3,000 daltons, the optimal ratio 5:1 (w/w) asso-
ciated with LPS neutralization and cytokine inhibition
would suggest a 1mole:1mole interaction between PCT
and LPS, which could use any of the above mentioned
interaction sites available on the PCT molecule.
Moreover, our results provide the first evidence of the
capability of PCT to significantly decrease the LPS-sti-
mulated release of the Treg cytokine IL-10 and chemo-
kine MCP-1 from human PBMC. The PCT-induced
decrease in the release of TNFα found with this experi-
mental model, agrees with the findings reported using a
different in vitro approach [5].
The late and significant decrease of LPS-stimulated IL-
10 may suggest a clinically valuable role of PCT in the
control of this cytokine during late stages of sepsis, often
associated with immunoparalysis, when IL-10 is reported
to play a pivotal role [19,20].
PCT and/or its fragment (e.g. N-PCT) have been shown
to cause some anti-inflammatory effects in some experi-
mental models [4]. In contrast, Becker et al. [3] reported
that PCT produced only detrimental effects in the host.According to our data and data from other investigators
[5,21], in clinical/experimental sepsis the large amount of
TNFα production and its detrimental effects for the host
may be controlled by PCT release. Unlike TNFα, which
mimics most of the LPS-induced signs and symptoms of
the sepsis [19], PCT did not show any detrimental effects
when injected in healthy animals [3,22] even at high dose.
Moreover, in septic hamster serum TNFα concentration
was not affected by PCT administration, which was able to
significantly decrease IL-1β serum level [6].
A very recent publication on the in vitro effect of PCT
on whole blood from healthy humans revealed that most
of the cytokines evaluated in the supernatant were not
affected by PCT. Only IL-6 exhibited a substantial in-
crease; whereas TNFα increased to a lesser extent and
IL-13 was significantly reduced by PCT. Human neutro-
phils challenged in vitro with several concentrations of
PCT did not significantly change cytokine release [23].
In human monocytes endogenous TNFα is crucial for
subsequent IL-10 synthesis through autocrine and para-
crine mechanisms [24]. Therefore, reduction of TNFα
levels by PCT may supposedly result in decreased IL-10
synthesis. Wiedermann et al. [25] reported that PCT was
able to decrease migration of monocytes towards differ-
ent chemoattractants including MCP-1. Moreover, N-
PCT has been found to reduce the expression of CD11b,
a major integrin involved in monocyte chemotaxis mech-
anism. Our data suggest a novel aspect of the PCT-
mediated control on monocyte chemotaxis, with a direct
decrease of LPS-induced MCP-1 by PCT. Based on our
results, in the presence of PCT, multiple mechanisms
would modulate monocyte chemotaxis, reducing sys-
temic inflammatory host response, which might follow
exaggerated activation of phagocytes during sepsis [26].
Cellular toxicity of PCT, LPS or PCT plus LPS should
not account for cytokine reduction by PCT, because the
direct assays of cell viability always indicated a percentage
of living cells higher than 95%, even after 24 hours of incu-
bation. Moreover, studied cytokines would be expected to
show substantial changes (due to cytotoxicity) with
addition of PCT alone, but this was not the case. The in-
crease of MCP-1 released by PBMC induced by LPS is ten
to twenty-fold higher than in PCT-stimulated PBMC. The
latter is not significantly different when compared to un-
stimulated PBMC incubated for 24 h (data not shown).
Even more importantly, the highest release of MCP-1 is
associated to the lowest concentration of PCT. Also cell
count was carried out at beginning and at the end of each
experiment and these values were not significantly differ-
ent. Therefore a decrease of cell number should be
excluded as a possible cause of reduced cytokine release,
during the experiments which involved PCT.
Despite the interest and novelty of the present find-
ings, the LPS neutralization might be only one of the
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storm” during sepsis. As the present study is based on an
in vitro model, some limitations regarding the drawing
of more general conclusions, the extrapolation to the
in vivo activity and the potential role of PCT in the ther-
apy of systemic inflammatory diseases are acknowledged.
Conclusions
In conclusion our data indicate a direct LPS neutralizing
effect of PCT, which suggests a significant PCT-induced
inhibition on major mediators of the Th1, Treg and
monocyte activation cascade stimulated by LPS. Any
agent, including PCT, with the capability to neutralize an
early stimulus such as a bacterial product (e.g. LPS) and
reduce the release of sepsis mediators deserves further
investigation. These reported findings may provide new




The LPS of E. coli strain O111:B4 was from Cambrex
(Walkersville, USA); the LPS of S. typhimurium strain
SL1102 was extracted and purified as previously
described [17]. Recombinant human procalcitonin was a
generous gift of Randox (Randox Laboratories Ltd.,
Crumlin, UK). RPMI 1640 medium was obtained from
Invitrogen (Carlsbad, CA).
LAL test
For the evaluation of the LPS-neutralizing activity of
PCT, LPS from S. typhimurium and E. coli were dis-
solved in sterile water for injection and then diluted in
apyrogenic saline fluid (SF). Serial dilutions of PCT
(5000, 500 and 50 pg/ml) in SF were incubated with
100 pg/ml of LPS from S. typhimurium and E. coli in a
sterile conic tube at 37°C for 30 min. In preliminary
experiments the reactivity of S. typhimurium and E. coli
LPS was tested at different time points following LPS-
PCT co-incubation. An incubation time of 30 min was
found to be optimal based on higher LPS reactivity in
the LAL test and more obvious PCT effect on such re-
activity (Quirino A. personal observation). The LPS-neu-
tralizing activity of PCT was analyzed using the
chromogenic LAL-test (QCL-1000, Cambrex, Walkers-
ville, USA) following manufacturer’s instructions, but the
results were reported as optical density (O.D.) at 405 nm
and were not corrected for the dilution factor [10].
PBMC stimulation
For the study of the effects of PCT-pre-incubated LPS in
cytokine release, human PBMC were obtained from
blood samples of healthy donors, who gave informed
consent.All procedures were conducted in accordance with the
guidelines of the local ethics committee at the Medical
Faculty of the University “Magna Graecia” of Catanzaro,
which are in compliance with Declaration of Helsinki
(59th WMA General Assembly, Seoul, October 2008).
Cells were isolated from heparinized whole blood by
Ficoll (Ficoll-Paque, SIGMA, Italy) density gradient puri-
fication technique. After washing with PBS and counting,
the cells were resuspended in RPMI 1640 medium in the
absence of antibiotics and glutamine. The cells were then
incubated in 24-well flat bottom tissue culture plates
(Falcon, Becton Dickinson Labware, Franklin Lakes, New
Jersey) at a final concentration of 1.5 × 105 cells/ml for 4
and 24 hours with LPS of S. typhimurium SL1102
(100 ng/ml). The latter was previously incubated for
30 min with different concentrations of PCT (5000-500-
50 ng/ml). Cells incubated with the same PCT concen-
trations in absence of LPS and cells incubated with LPS
in absence of PCT, were used as controls.
The cytotoxicity of PCT, LPS and PCT plus LPS was
tested by trypan blue test (11) and by acridine orange
vital staining, after both 4 and 24 h of PBMC incubation.
In all cases the percentage of viable cells was higher than
95%. Also cell count was carried out at beginning and at
the end of each experiment and these values were not
significantly different.
Supernatants from PBMC cultures were collected and
assayed for simultaneous determination of Th1, Th2 and
Treg cytokines using a cytokine biochip array on the Evi-
dence Investigator analyser following the manufacturer’s
instructions (Randox Laboratories Ltd., Crumlin, UK).
For this study data on IL-10, IL-4, TNFα and MCP-1
were evaluated.Statistical analysis
Statistical significance between groups was assessed by
the Student’s t test. Results were presented as means ±
SEM of at least four experiments each carried out in du-
plicate. A p value <0.05 was considered to be statistically
significant.
Abbreviations
PCT: Procalcitonin; LPS: Lipopolysaccharide; LAL: Limulus amoebocyte lysate;
PBMC: Peripheral blood mononuclear cell; IL-10: Interleukin-10; TNFα: Tumor
necrosis factor alpha; MCP-1: Monocyte chemotactic protein-1; CT: Calcitonin;
TLR-4: Toll-like receptor 4; S. typhimurium: Salmonella typhimurium; E.
coli: Escherichia coli; SF: Saline fluid; O.D: Optical density; SEM: Standard error
of the mean.
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